John Armitage’s AbbVie ABBV Stock Holding History

John Armitage’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-3,899,611	Closed	-$255M	–	36
2014 Q4	$255M	Buy	+3,899,611	New	+$246M	3.42%	13

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

John Armitage's ABBV Position: Q1 2015 in Review

John Armitage sold out of AbbVie (ABBV) in Q1 2015, closing a stake of 3,899,611 shares — an estimated $255M sold.

John Armitage first reported a position in ABBV in Q4 2014 and held it in 1 quarter. The position peaked at $255M in Q4 2014. 1,601 funds tracked by Wall St. Rank hold ABBV as of Q1 2015.

John Armitage reported no remaining AbbVie position as of Q1 2015 after selling out during the quarter.
John Armitage sold 3,899,611 AbbVie shares in Q1 2015, an estimated $255M.
John Armitage first reported a position in AbbVie in Q4 2014 and held it in 1 quarter.
John Armitage's AbbVie position peaked at $255M in Q4 2014.
1,601 funds tracked by Wall St. Rank held AbbVie as of Q1 2015.

Based on Egerton Capital (UK)'s 13F filing for Q1 2015, filed 11 May 2015.